FY2027 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA) – Investment analysts at HC Wainwright raised their FY2027 EPS estimates for Savara in a report issued on Tuesday, December 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.16) for the year, up from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2028 earnings at $0.13 EPS.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01).

Several other research analysts have also recently issued reports on SVRA. UBS Group set a $10.00 target price on shares of Savara in a report on Tuesday. Citizens Jmp dropped their price objective on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 13th. Citigroup reissued an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. Oppenheimer set a $10.00 target price on Savara in a report on Tuesday. Finally, Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.13.

Savara Stock Performance

Shares of Savara stock opened at $6.40 on Thursday. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The stock’s fifty day moving average price is $5.12 and its 200-day moving average price is $3.66. The firm has a market cap of $1.30 billion, a P/E ratio of -12.07 and a beta of 0.23. Savara has a 12 month low of $1.89 and a 12 month high of $7.01.

Institutional Investors Weigh In On Savara

A number of large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in Savara during the third quarter valued at $44,000. Prudential Financial Inc. purchased a new stake in Savara in the second quarter valued at $30,000. BNP Paribas Financial Markets boosted its holdings in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Finally, May Hill Capital LLC acquired a new stake in Savara during the 2nd quarter worth about $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.